Welcome to the April edition of INNsight Newsletter, where we share with you the latest news and insights from IQVIA Global Market Insights.
This month's thought leadership includes:
Connect with us
Pharma Deals Review of 2023
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios
Seeking New Horizons: Where Innovators Find Opportunities in a Fast-Changing Immunology Landscape
Litigation and Events
THOUGHT LEADERSHIP
PHARMA DEALS REVIEW OF 2023
The whitepaper highlights a significant downturn in the life sciences sector’s deal activity, with a 27% decline in both M&A and licensing deals compared to 2022, driven by market volatility and increased capital costs. It notes a 36% reduction in collaborative R&D alliances, marking a 5-year low, as companies narrowed their focus on therapeutic areas. These insights suggest a cautious approach to deal-making and a strategic reprioritization within the industry.
Read more
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios
In this report, we characterize the current state of these therapies across the product lifecycle, beginning with pre-commercial activities such as funding and clinical research. We also detail the hurdles to commercialization, including infrastructure needs, reimbursement, and patient access. It also provides potential future scenarios across eight indicators to understand the evolution of the sector through 2035 and beyond. Read more
Seeking New Horizons: Where Innovators Find Opportunities In A Fast-Changing Immunology Landscape
Immunology has been a powerhouse for the biopharmaceutical industry, growing at a rate 3-5 times faster than the overall pharmaceutical market and is projected to hit $166 billion by the end of 2024. However, the sector is facing a slowdown, with growth expected to decelerate from a 15% compound annual growth rate (CAGR) to just 2-5% over the next five years, falling below the industry average for the first time. Read
more
LITIGATION UPDATE
Court of Appeals Affirms the Unpatentability of Pfizer’s Pneumococcal Vaccine Patent
Pfizer owns the US9492559 (US ‘559) patent which covers the antigenic preparation of Streptococcus pneumoniae glycoconjugates for use in pneumococcal vaccines. The S. pneumoniae vaccine is indicated for prevention of infectious diseases such as pneumonia, febrile bacteremia and meningitis by priming the immune system. Read more
EVENTS
CPHI Japan
17 - 19 April 2024, Tokyo, Japan
Join our IQVIA Global Markets Insights’ team at CPHI, where we will be exhibiting and presenting a session on Technology Driving Change and Opportunity in the Japan Pharmaceutical Market. Learn how to leverage data intelligence innovations, to empower data-informed decisions, to enhance your business and ultimately maximize your outcomes. Find us on stand 4D-01.More information
Should you have a colleague who is interested in subscribing to this newsletter, please ask them to register here.
Information provided by you may be collected and automatically stored in our database and may be used for sending you additional information about IQVIA and our services. Such information also may be transferred to IQVIA companies in other countries.
If you do not wish to receive further information from IQVIA please opt-out. Copyright 2024 IQVIA Holdings Inc. and its affiliates. All rights reserved.
Please note that this message was sent to the following email address: jane.lu3@iqvia.com